William Rigby - Publications

Dartmouth College, Hanover, NH, United States 
Microbiology Biology

47 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Jones JD, Hamilton BJ, Skopelja S, Rigby WF. Induction of interleukin-6 production by rituximab in human B cells. Arthritis & Rheumatology (Hoboken, N.J.). 66: 2938-46. PMID 25080282 DOI: 10.1002/art.38798  1
2014 Pritchard CH, Greenwald MW, Kremer JM, Gaylis NB, Rigby W, Zlotnick S, Chung C, Jaber B, Reiss W. Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study. Bmc Musculoskeletal Disorders. 15: 177. PMID 24884454 DOI: 10.1186/1471-2474-15-177  1
2014 Jones JD, Hamilton BJ, Challener GJ, de Brum-Fernandes AJ, Cossette P, Liang P, Masetto A, Ménard HA, Carrier N, Boyle DL, Rosengren S, Boire G, Rigby WF. Serum C-X-C motif chemokine 13 is elevated in early and established rheumatoid arthritis and correlates with rheumatoid factor levels. Arthritis Research & Therapy. 16: R103. PMID 24766912 DOI: 10.1186/ar4552  1
2013 Rigby WF, Mease PJ, Olech E, Ashby M, Tole S. Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study. The Journal of Rheumatology. 40: 599-604. PMID 23547218 DOI: 10.3899/jrheum.120924  1
2013 Jones JD, Shyu I, Newkirk MM, Rigby WF. A rheumatoid factor paradox: inhibition of rituximab effector function. Arthritis Research & Therapy. 15: R20. PMID 23351360 DOI: 10.1186/ar4152  1
2013 Jones JD, Hamilton BJ, Rigby WF. Reply: To PMID 22674374. Arthritis and Rheumatism. 65: 1132-3. PMID 23335046 DOI: 10.1002/art.37870  1
2013 Weinblatt ME, Kremer J, Cush J, Rigby W, Teng LL, Devenport J, Singh N, Lepley D, Genovese MC. Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study. Arthritis Care & Research. 65: 362-71. PMID 22972745 DOI: 10.1002/acr.21847  1
2012 Jones JD, Hamilton BJ, Rigby WF. Rituximab mediates loss of CD19 on B cells in the absence of cell death. Arthritis and Rheumatism. 64: 3111-8. PMID 22674374 DOI: 10.1002/art.34560  1
2012 Jones JD, Albert DA, Thadani V, Rigby WF. Unusual case of a swollen painful toe in a young man. Arthritis Care & Research. 64: 298-302. PMID 22278969 DOI: 10.1002/acr.20603  1
2011 Rigby W, Ferraccioli G, Greenwald M, Zazueta-Montiel B, Fleischmann R, Wassenberg S, Ogale S, Armstrong G, Jahreis A, Burke L, Mela C, Chen A. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care & Research. 63: 711-20. PMID 21557525 DOI: 10.1002/acr.20419  1
2011 Nichols RC, Botson J, Wang XW, Hamilton BJ, Collins JE, Uribe V, Brooks SA, Zan M, Rigby WF. A flexible approach to studying post-transcriptional gene regulation in stably transfected mammalian cells. Molecular Biotechnology. 48: 210-7. PMID 21153715 DOI: 10.1007/s12033-010-9360-8  1
2010 Williams CM, Storm CA, Burns C, Rigby W, Dinulos JG. Ichthyotic-appearing skin changes associated with childhood morphea, systemic sclerosis, and systemic lupus erythematosus/scleroderma overlap. Pediatric Dermatology. 27: 170-3. PMID 20537069 DOI: 10.1111/j.1525-1470.2010.01108.x  1
2010 Østergaard M, Baslund B, Rigby W, Rojkovich B, Jorgensen C, Dawes PT, Wiell C, Wallace DJ, Tamer SC, Kastberg H, Petersen J, Sierakowski S. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis and Rheumatism. 62: 2227-38. PMID 20506254 DOI: 10.1002/art.27524  1
2008 Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Engle XA, Rigby WF, Pioli PA, Guyre PM, Conejo-Garcia JR. PILAR is a novel modulator of human T-cell expansion. Blood. 112: 1259-68. PMID 18550855 DOI: 10.1182/blood-2007-12-130773  1
2007 Rigby WF. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior? Nature Clinical Practice. Rheumatology. 3: 227-33. PMID 17396108 DOI: 10.1038/ncprheum0438  1
2005 Rigby WF, Roy K, Collins J, Rigby S, Connolly JE, Bloch DB, Brooks SA. Structure/function analysis of tristetraprolin (TTP): p38 stress-activated protein kinase and lipopolysaccharide stimulation do not alter TTP function. Journal of Immunology (Baltimore, Md. : 1950). 174: 7883-93. PMID 15944294  1
2005 Rigby WF. Distinct mechanisms of action of tumor necrosis factor antagonists: what are the clinical implications? Seminars in Arthritis and Rheumatism. 34: 1-2. PMID 15852246 DOI: 10.1016/j.semarthrit.2005.01.001  1
2004 Bériault V, Clément JF, Lévesque K, Lebel C, Yong X, Chabot B, Cohen EA, Cochrane AW, Rigby WF, Mouland AJ. A late role for the association of hnRNP A2 with the HIV-1 hnRNP A2 response elements in genomic RNA, Gag, and Vpr localization. The Journal of Biological Chemistry. 279: 44141-53. PMID 15294897 DOI: 10.1074/jbc.M404691200  1
2004 Brooks SA, Connolly JE, Rigby WF. The role of mRNA turnover in the regulation of tristetraprolin expression: evidence for an extracellular signal-regulated kinase-specific, AU-rich element-dependent, autoregulatory pathway. Journal of Immunology (Baltimore, Md. : 1950). 172: 7263-71. PMID 15187101  1
2003 Fairhurst AM, Connolly JE, Hintz KA, Goulding NJ, Rassias AJ, Yeager MP, Rigby W, Wallace PK. Regulation and localization of endogenous human tristetraprolin. Arthritis Research & Therapy. 5: R214-25. PMID 12823857 DOI: 10.1186/ar778  1
2003 Hamilton BJ, Genin A, Cron RQ, Rigby WF. Delineation of a novel pathway that regulates CD154 (CD40 ligand) expression. Molecular and Cellular Biology. 23: 510-25. PMID 12509450 DOI: 10.1128/MCB.23.2.510-525.2003  1
2002 Brooks SA, Connolly JE, Diegel RJ, Fava RA, Rigby WF. Analysis of the function, expression, and subcellular distribution of human tristetraprolin. Arthritis and Rheumatism. 46: 1362-70. PMID 12115244 DOI: 10.1002/art.10235  1
2002 Pioli PA, Hamilton BJ, Connolly JE, Brewer G, Rigby WF. Lactate dehydrogenase is an AU-rich element-binding protein that directly interacts with AUF1. The Journal of Biological Chemistry. 277: 35738-45. PMID 12107167 DOI: 10.1074/jbc.M204002200  1
2001 Pioli PA, Rigby WF. The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression. The Journal of Biological Chemistry. 276: 40346-52. PMID 11517223 DOI: 10.1074/jbc.M105391200  1
2000 Brooks SA, Rigby WF. Characterization of the mRNA ligands bound by the RNA binding protein hnRNP A2 utilizing a novel in vivo technique. Nucleic Acids Research. 28: E49. PMID 10773097  1
1999 Rigby WFC, Waugh MG, Hamilton BJ. Characterization of RNA binding proteins associated with CD40 ligand (CD154) mRNA turnover in human T lymphocytes Journal of Immunology. 163: 4199-4206. PMID 10510356  1
1997 Hamilton BJ, Burns CM, Nichols RC, Rigby WFC. Modulation of AUUUA response element binding by heterogeneous nuclear ribonucleoprotein A1 in human T lymphocytes: The roles of cytoplasmic location, transcription, and phosphorylation Journal of Biological Chemistry. 272: 28732-28741. PMID 9353343 DOI: 10.1074/jbc.272.45.28732  1
1995 Henics T, Nagy E, Rigby WFC. Combined application of in vivo UV-crosslinking and in vitro label transfer in the examination of Au-rich sequence binding protein - RNA interactions Cell Biology International. 19: 791-801. PMID 7581230 DOI: 10.1006/cbir.1995.1131  1
1995 Nagy E, Rigby WFC. Glyceraldehyde-3-phosphate dehydrogenase selectively binds AU-rich RNA in the NAD+-binding region (Rossmann fold) Journal of Biological Chemistry. 270: 2755-2763. PMID 7531693 DOI: 10.1074/jbc.270.6.2755  1
1993 Hamilton BJ, Nagy E, Malter JS, Arrick BA, Rigby WFC. Association of heterogeneous nuclear ribonucleoprotein A1 and C proteins with reiterated AUUUA sequences Journal of Biological Chemistry. 268: 8881-8887. PMID 8473331  1
1993 Gosselin EJ, Wardwell K, Rigby WFC, Guyre PM. Induction of MHC class II on human polymorphonuclear neutrophils by granulocyte/macrophage colony-stimulating factor, IFN-γ, and IL-31 Journal of Immunology. 151: 1482-1490. PMID 8335942  1
1992 Rigby WFC, Waugh MG. Decreased accessory cell function and costimulatory activity by 1,25-dihydroxyvitamin D3-treated monocytes Arthritis and Rheumatism. 35: 110-119. PMID 1370618  1
1991 Connor RI, Rigby WFC. 1α,25-Dihydroxyvitamin D3 inhibits productive infection of human monocytes by HIV-1 Biochemical and Biophysical Research Communications. 176: 852-859. PMID 1673842 DOI: 10.1016/S0006-291X(05)80264-5  1
1990 Rigby WFC, Waugh M, Graziano RF. Regulation of human monocyte HLA-DR and CD4 antigen expression, and antigen presentation by 1,25-dihydroxyvitamin D3 Blood. 76: 189-197. PMID 2364169  1
1990 Rigby WFC, Hamilton BJ, Waugh MG. 1,25-dihydroxyvitamin D3 modulates the effects of interleukin 2 independent of IL-2 receptor binding Cellular Immunology. 125: 396-414. PMID 2105168 DOI: 10.1016/0008-8749(90)90094-8  1
1988 Rigby WFC. The immunobiology of vitamin D Immunology Today. 9: 54-58. PMID 3076760  1
1987 Rigby WFC, Yirinec B, Oldershaw RL, Fanger MW. Comparison of the effects of 1,25-dihydroxyvitamin D3 on T lymphocyte subpopulations European Journal of Immunology. 17: 563-566. PMID 3106071  1
1987 Rigby WFC, Denome S, Fanger MW. Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA Journal of Clinical Investigation. 79: 1659-1664. PMID 2884234  1
1986 Li S, Maliszewski CR, Rigby WFC, Fanger MW. IgA-mediated effector function of HL-60 cells following treatment with calcitriol Molecular Immunology. 23: 611-618. PMID 3462486 DOI: 10.1016/0161-5890(86)90097-0  1
1985 Rigby WFC, Shen L, Ball ED, Fanger MW. 1,25-dihydroxyvitamin D3 induces a myelomonocytic phenotype with enhanced effector cell function in the HL-60 promyelocytic leukemia cell line Molecular Immunology. 22: 567-572. PMID 3860730 DOI: 10.1016/0161-5890(85)90180-4  1
1985 Rigby WFC, Noelle RJ, Krause K, Fanger MW. The effects of 1,25-dihydroxyvitamin D3 on human T lymphocyte activation and proliferation: A cell cycle analysis Journal of Immunology. 135: 2279-2286. PMID 2993410  1
1985 Rigby WFC, Ball ED, Guyre PM, Fanger MW. The effects of recombinant-DNA-derived interferons on the growth of myeloid progenitor cells Blood. 65: 858-861. PMID 2579688  1
1985 Shen L, Maliszewski CR, Rigby WFC, Fanger MW. HL-60 cell differentiation induced by vitamin D3 is accompanied by IgA Fc receptor expression Federation Proceedings. 44.  1
1984 Rigby WFC, Shen L, Ball ED, Guyre PM, Fanger MW. Differentiation of a human monocytic cell line by 1,25-dihydroxyvitamin D3 (calcitriol): A morphologic, phenotypic, and functional analysis Blood. 64: 1110-1115. PMID 6548394  1
1984 Ball ED, Guyre PM, Glynn JM, Rigby WF, Fanger MW. Modulation of class I HLA antigens on HL-60 promyelocytic leukemia cells by serum-free medium: Re-induction by γ-IFN and 1,25-dihydroxyvitamin D3 (calcitriol) Journal of Immunology. 132: 2424-2428. PMID 6425403  1
1984 Rigby WFC, Stacy T, Fanger MW. Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol) Journal of Clinical Investigation. 74: 1451-1455. PMID 6332829  1
1984 Doble EA, Rigby WFC, Shen L. In vitro differentiation of U937 cells: Synergy between 1,25(OH)2-D3 and gamma interferon Federation Proceedings. 43.  1
Show low-probability matches.